159 related articles for article (PubMed ID: 29809277)
21. [Standard therapies for acute myeloid leukemia].
Matsumura I
Rinsho Ketsueki; 2009 Oct; 50(10):1389-400. PubMed ID: 19915347
[No Abstract] [Full Text] [Related]
22. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98.
von Neuhoff C; Reinhardt D; Sander A; Zimmermann M; Bradtke J; Betts DR; Zemanova Z; Stary J; Bourquin JP; Haas OA; Dworzak MN; Creutzig U
J Clin Oncol; 2010 Jun; 28(16):2682-9. PubMed ID: 20439630
[TBL] [Abstract][Full Text] [Related]
23. Enterocolitis as initial presentation of acute myelogenous leukemia exacerbated by induction chemotherapy with idarubicin-cytosine arabinoside.
Wood RA
Mayo Clin Proc; 2002 Oct; 77(10):1133. PubMed ID: 12374257
[No Abstract] [Full Text] [Related]
24. Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients.
Kim I; Koh Y; Yoon SS; Park S; Kim BK; Kim DY; Lee JH; Lee KH; Cheong JW; Lee HK; Kim SH; Kim H; Joo YD; Lee SM; Won JH; Park SK; Hong DS; Kim SH; Sohn SK; Kim CS; Park E; Kim MK; Park MR; Lee JH; Min YH;
Am J Hematol; 2013 Jan; 88(1):10-5. PubMed ID: 23077109
[TBL] [Abstract][Full Text] [Related]
25. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia.
Kadia T; Kantarjian H; Garcia-Manero G; Borthakur G; Wang X; Patel K; Jabbour E; Brandt M; Daver N; Pemmaraju N; Pierce S; Cortes J; Ravandi F
Br J Haematol; 2015 Aug; 170(4):590-3. PubMed ID: 25716073
[No Abstract] [Full Text] [Related]
27. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
28. Idarubicin plus cytarabine as first-line treatment of acute nonlymphoblastic leukemia.
Lambertenghi-Deliliers G; Annaloro C; Cortelezzi A; Cortellaro M; Della Volpe A; Maiolo AT; Mozzana R; Pogliani E; Pozzoli E; Polli EE
Semin Oncol; 1989 Feb; 16(1 Suppl 2):16-20. PubMed ID: 2928806
[No Abstract] [Full Text] [Related]
29. Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged ≥ 60 years.
Österroos A; Eriksson A; Antunovic P; Cammenga J; Deneberg S; Lazarevic V; Lorenz F; Möllgård L; Derolf ÅR; Uggla B; Wennström L; Ölander E; Höglund M; Juliusson G; Lehmann S
Br J Haematol; 2020 Apr; 189(1):e13-e16. PubMed ID: 32103493
[No Abstract] [Full Text] [Related]
30. Prospective, multicenter, phase II study on reducing the dosage of idarubicin and FLAG for patients younger than 65 years with resistant acute myeloid leukemia: a comparison with a higher dosage trial.
Kim H; Lee JH; Joo YD; Bae SH; Lee JH; Kim DY; Lee WS; Ryoo HM; Jo JC; Park JH; Lee KH
Acta Haematol; 2014; 132(1):87-96. PubMed ID: 24513865
[TBL] [Abstract][Full Text] [Related]
31. Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Human Leukocyte Antigen-Mismatched Stem Cell Microtransplantation Improved Outcomes in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Zhu Y; Zhao H; Zhang X; Wu Y; Xie Y; Li Y; Lian Y; Huang J; Li J; Chen Y; Qian S
Biol Blood Marrow Transplant; 2017 May; 23(5):830-835. PubMed ID: 28189902
[TBL] [Abstract][Full Text] [Related]
32. Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation.
Parovichnikova EN; Loukianova IA; Troitskaya VV; Drokov MY; Lobaova TI; Kuzmina LA; Sokolov AN; Kokhno AV; Fidarova ZT; Baskhaeva GA; Gavrilina OA; Vasilyeva VA; Obukhova TN; Kuznetsova SA; Sudarikov AB; Dvirnik VN; Galtseva IV; Davidiva JO; Kulikov SM; Savchenko VG
Ter Arkh; 2018 Aug; 90(7):14-22. PubMed ID: 30701918
[TBL] [Abstract][Full Text] [Related]
33. Venetoclax plus decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation.
Andreani G; Dragani M; Serra A; Nicoli P; De Gobbi M; Cilloni D
Am J Hematol; 2019 Feb; 94(2):E48-E50. PubMed ID: 30431666
[No Abstract] [Full Text] [Related]
34. A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia.
Wiernik PH; Case DC; Periman PO; Arlin ZA; Weitberg AB; Ritch PS; Todd MB
Semin Oncol; 1989 Feb; 16(1 Suppl 2):25-9. PubMed ID: 2928807
[No Abstract] [Full Text] [Related]
35. HLA-partially matched cellular therapy (stem-cell microtransplantation) for acute myeloid leukaemia: description of four cases.
Forés R; Dorado N; Vilches C; Regidor C; García-Marco JA; de Pablo R; de Laiglesia A; Lario A; Piris M; Cabrera JR
Br J Haematol; 2014 May; 165(4):580-1. PubMed ID: 24666200
[No Abstract] [Full Text] [Related]
36. Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8.
Koh Y; Kim I; Bae JY; Song EY; Kim HK; Yoon SS; Lee DS; Park SS; Park MH; Park S; Kim BK
Jpn J Clin Oncol; 2010 Nov; 40(11):1037-45. PubMed ID: 20587614
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of extramedullary relapses is higher after allogeneic stem cell transplantation than after chemotherapy in adult patients with acute myeloid leukemia.
Shimizu H; Saitoh T; Hatsumi N; Takada S; Handa H; Jimbo T; Sakura T; Miyawaki S; Nojima Y
Leuk Res; 2013 Nov; 37(11):1477-81. PubMed ID: 24054717
[TBL] [Abstract][Full Text] [Related]
38. The effect of decreased-dose idarubicin for elderly patients with acute myeloid leukemia.
Kobayashi T; Ichikawa M; Nannya Y; Kurokawa M
Jpn J Clin Oncol; 2013 Oct; 43(10):1047-51. PubMed ID: 23956441
[TBL] [Abstract][Full Text] [Related]
39. Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.
Maurillo L; Buccisano F; Spagnoli A; Voso MT; Fianchi L; Papayannidis C; Gaidano GL; Breccia M; Musto P; De Bellis E; Del Principe MI; Lunghi M; Lessi F; Martinelli G; Venditti A
Ann Hematol; 2018 Oct; 97(10):1767-1774. PubMed ID: 29947973
[TBL] [Abstract][Full Text] [Related]
40. Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression.
Shi P; Zha J; Guo X; Chen F; Fan Z; Huang F; Meng F; Liu X; Feng R; Xu B
Pharmacogenomics; 2013 Jan; 14(1):17-23. PubMed ID: 23252945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
